Topiramate & Sodium Valproate: Resources and Information
MHRA Alerts & Updates
MHRA drug safety update - February 2025
MHRA Drug Safety Update - January 2024
MHRA National Patient Safety Alert - November 2023 (NatPSA/2023/013/MHRA)
MHRA - Valproate: review of safety data and expert advice on management of risks
PTHB Local Governance & Updates
PTHB Medicines Safety Group - Valproate Alert Update (May 2024)
PTHB Valproate Oversight Group - Terms of Reference (January 2024) [Historical]
The PTHB Valproate Oversight Group was established to support the implementation of national valproate safety requirements. The group is no longer active, with ongoing oversight and governance of valproate safety now undertaken through the PTHB Medicines Safety Group (MSG).
Resources
MHRA - Patient Guide: What you need to know about valproate
All Wales Therapeutics and Toxicology Centre - Sodium valproate use by women and girls
As part of the collaborative effort of the Sodium Valproate Task Force established by Welsh Government, AWTTC (All Wales Therapeutics and Toxicology Centre) are pleased to announce that a hub of information focusing on ‘Sodium valproate use by women and girls’ is now available on their website, accessed using the link above.
Easy read leaflet for female medicine reviews
Decision Support Tools
Decision Support Tool: Bipolar Disorder - Is Valproate the Right Treatment for me?
Decision Support Tool: Is Valproate the Right Epilepsy Treatment for me?
PTHB Valproate Prescribing Policy
MMP 452 - Valproate Prescribing V1
Forms
MHRA - Annual Risk Acknowledgement Form for Female Patients
MHRA - Risk Acknowledgement Form for Male Patients Starting Valproate
Guidance
MHRA - Guide for Healthcare Professionals: Information on the risks of valproate use in all patients
MHRA - Valproate: Review of Safety Data and Expert Advice on Management of Risks
All Wales Therapeutics and Toxicology Centre - Sodium valproate use by women and girls
As part of the collaborative effort of the Sodium Valproate Task Force established by Welsh Government, AWTTC (All Wales Therapeutics and Toxicology Centre) are pleased to announce that a hub of information focusing on ‘Sodium valproate use by women and girls’ is now available on their website, accessed using the link above.
Paediatric Patients
RCPCH - Prescribing Valproate to Female Patients Under 18 Years of Age (Jan 2024)
RCPCH - Update for Valproate Prescribing in Paediatric Neurology (Jan 2024)